Diagnosis and treatment of digestive cancer by means of monoclonal antibodies

点击翻译按钮获取中文摘要

1:Monoclonal antibodies against pancreatic cancer associated antigen from malignant pancreatic ascites were prepared. These antibodies showed high specificities against pancreatic cancer by immunohistological study. Monoclonal antibodies against fetal pancreas (FP-1,FP-2 and FP-3) were characterized. FP-1 ,FP-2 and FP-3 reacted respectively with ductal cells,acinar cells and islet cells. FP-1 recognized peptide and reacted with 15/21 of pancreatic cancer tissues.FP-2 and FP-3 recogognized carbohydrate and FP-3 reacted with 8/13 of Apudomas(medullary thyroid carcinomas, intestinal carcinoids and pheochromocytomas).2:Using specific anti-CEA monoclonal antibody,an enzyme-immunoassay for circulating CEA-IC has been developed. From a group of 28 healthy volunteers,an upper limit of 8U/ml has been tentatively determined. An elevated CEA-IC was shown in 53%(10/19) of patients with metastatic or recurrent colo rectal cancer,3 of them were of normal value of CEA. CEA-IC had a molecular weight of 440,000 or more biochemically.3.To develop appropriate assay system of fecal CEA determinations for screening of GI cancer patients, further study would be thought to be necessary from our research. 4.Human-Human hybridomas were prepared. Screening and characterization of these hybridomas were now underway. For tumor imaging and targeting, we are now developing <^(19)F> -Magnetic Resonance Imaging with high tesla system.